

Subcutaneous Injection Devices to 2028

Devices, Markets,
Therapeutics, Strategies &
Forecasts

Report Brochure



Greystone
Research Associates

Greystone Research Associates is pleased to announce the publication of a new market assessment. **Subcutaneous Injection Devices to 2028: Devices, Markets, Players, Strategies and Forecasts** is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for subcutaneous injection devices. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Evolution in Therapeutic Care

Because of the ongoing need for repeat dosing posed by chronic diseases, these indications represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver. For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market.




Table of Contents

Executive Summary	Antares Pharma Autoinjectors
The Market Opportunity	Dali Medical Devices
Delivery Market Dynamics	Development-stage Autoinjectors
The Economics of Injectable Drugs	NIS Autoinjector (Midas Pharma)
What's Driving the Growth in Injectable Devices?	ArQ – Bios (Oval Medical)
Prefilled Syringes Proliferating	ArQ – Tempo (Oval Medical)
The Trend toward Self- Administration	ArQ – Vita (Oval Medical)
Shifting Demographics	Wirelessly Enabled Autoinjectors
Innovation in Disposable Device Designs	BETACONNECT (Bayer)
Proliferation of Biological Drugs	DataPen (Biocorp)
Therapeutic Monoclonal Antibodies	OneJet (Biocorp)
Therapeutic Demand Drivers	Alubena (SHL Medical)
Competitive Landscape	Flexi-Q eMU (Elcam Medical)
Risk Factors	RebiSmart (Merck Serono)
Autoinjectors – Commercial Devices	Selected Product Specific Autoinjectors
Manual Injection Autoinjectors	Alsuma/Sumatriptan Autoinjector
Automated Injection Autoinjectors	Sumatriptan (Dr. Reddy's)
Disposable Autoinjectors	Rebif/Rebidose (Merck Serono)
Molly (SHL Medical)	Aimovig (Amgen/Novartis)
Molly RNS (SHL Medical)	Enbrel Mini AutoTouch (Amgen)
Bertha (SHL Medical)	Pegasys Proclick (Genentech/Roche)
Maggie (SHL Medical)	Otrexup (Antares Pharma)
Amber (SHL Medical)	Evzio (Kaleo)
SafeLock (SHL Medical)	Epinephrine (Various)
VSDI +NIT (SHL Medical)	Autoinjector Device Design Factors
SDI MIX +NIT (SHL Medical)	Material Selection Issues
Syrina S (Consort Medical)	Part Counts and Device Cost
Syrina AS (Consort Medical)	Safety Features
AutoJect 2 (Owen Mumford)	Needle Insertion Depth
SelfDose (West Pharmaceutical Services)	Failsafe Activation
Flexi-Q PFS (Elcam Medical)	Dose Inspection/Injection Confirmation
OTS Autoinjector (Consort Medical)	Lyophilized Drugs/Reconstitution
Pro-Ject (Aptar)	Human Engineering/Ergonomics
Consort Medical ASI	Pen Injectors
Ypsomed VarioJect	Pen Injector Design Selection Factors
Rotaject Technology (SHL Medical)	Standardized Pen Platforms
Viscala Autoinjector (Consort Medical)	Haselmeier
Flexi-Q HV (Elcam Medical)	Becton Dickinson
Intevia (Becton Dickinson)	Owen Mumford
	Ypsomed
	SHL Medical
	Custom Pen Designs

Table of Contents

Reusable Pens	Mechanical Disposable
Dual Chamber Pens	enFuse (Enable Injections)
Emerging Devices	Captive Devices
Commercial Pen Products	sc2Wear Infusor (scPharmaceuticals)
Genotropin Pen	PatchPump (SteadyMed)
Humatro-Pen/Humatro Pen 3	Wireless Data
Norditropin	Key Therapeutic Sector Analysis
NordiPenmate	Anaphylaxis/Countermeasures
Nutropin AQ Pen	Autoimmune Diseases
Omnitrope	Rheumatoid Arthritis
One.Click	Psoriasis
Lantus/Toujeo (Insulin Glargine)	Multiple Sclerosis
Diapen	Exenatide (Byetta)
Gansulin Pen	Bydureon
Flexpen (Novo Nordisk)	Pramlintide (Symlin)
Humalog Pen/KwikPen	Abliglutide (Tanzeum)
HumaPen Memoir	Hepatitis
HumaPen Luxura HD	Hormones
NovoPen (Novo Nordisk)	Osteoporosis
SoloStar	Market Factors
Byetta Pen	Regulatory Issues
Bydureon	Device Branding
SymlinPen	Patient Adherence and Ease of Use
Saxenda (Liraglutide)	Healthcare Economics
Tanzeum (Abliglutide)	Company Profiles
Trulicity (Dulaglutide)	
Victoza (Liraglutide)	
Parathyroid Hormone	
Forteo Pen	
Preatact/Preos	
Natpara	
Reproductive Hormones	
Follistim/Puregon Pen	
Gonal-f	
Other Handheld Devices	
Needle-free Injectors	
Wearable Devices	
Patch Pumps	
Large Volume Wearable Devices	
Product Analysis and Assessments	
Libertas (Becton Dickinson)	
Neulasta OnPro Injector (Insulet/Amgen)	
Patch Pump (Sensile Medical)	
SmartDose (West Pharmaceuticals)	
YpsoDose (Ypsomed)	
Electronic Semi-disposable	
E3D Patch Pump (Elcam)	

What You Will Learn

- Provides detailed analysis of subcutaneous drug products, drug delivery and device strategies, and product development factors
- Assesses key markets, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments
- Provides market data and forecasts to 2028
- Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of alliances and partnerships on subcutaneous drug product commercialization
- Evaluates the impact of economic, technology, and regulatory factor

Report Format and Availability

This report is available electronic format. A site license for a single physical location and a corporate license are also available. Custom licensing options to address specific company user requirements are available by calling client services at 603-440-5710, or by emailing clientservices@greystoneassociates.org.

Methodology

Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Associates

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Ordering Information

Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address and billing address.

Payment

We accept the following forms of payment:

Company Check: Please make checks payable to 'Greystone Associates'

Credit Cards: We accept MasterCard, Visa and American Express

Wire Transfers: See 'Wire Transfers' below for more information

Orders Outside the U.S.

Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer.

Email to
research@greystoneassociates.org

Wire Transfers: TD Banknorth
300 Franklin Street
Manchester, NH 03103
(Call for Account Information)

Mailing Address: Greystone Research Associates
Client Services
P.O. Box 1362
Amherst, NH 03031

Subcutaneous Injection Devices to 2028

Devices, Markets, Therapeutics, Strategies and Forecasts

Select	Format	License	Price (U.S. Funds)	Total
<input type="checkbox"/>	PDF	Single User License	\$4,850.00	
<input type="checkbox"/>	PDF	Site License	\$6,500.00	
<input type="checkbox"/>	PDF	Global License	\$9,500.00	
Total Payment (U.S. funds)				

Method of Payment: ___ Company Check ___  ___  ___  ___ Wire Transfer (International)

Card Number: _____ Name on Card _____

Expiration Date: _____ Card CVV _____ Signature _____

Billing Information	Shipping Information
Name:	<input type="checkbox"/> Click here if same as Billing Information Name:
Title:	Title:
Company:	Company:
Street Address:	Street Address:
City,State/Province:	City,State/Province:
Country/Postal Code:	Country/Postal Code:
Phone:	Phone:
Fax:	Fax:
Email:	Email: